 | • レポートコード：GIR-107A12083 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、B細胞慢性リンパ性白血病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。B細胞慢性リンパ性白血病治療の種類別市場規模（AMG-319、ATTCK-20、IDD-002、JNJ-64052781、レナリドマイド、MAT-303、MT-3724、その他）、用途別市場規模（クリニック、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・B細胞慢性リンパ性白血病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AB Science SA、Amgen Inc.、Celgene Corporation、Dynavax Technologies Corporation、Eisai、Elsalys Biotech SAS、F. Hoffmann-La Roche Ltd.、iDD biotech SAS、Immunomedics, Inc.、Johnson & Johnson、Juno Therapeutics Inc.、Molecular Templates Inc.、Noxxon Pharma AG ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：AMG-319、ATTCK-20、IDD-002、JNJ-64052781、レナリドマイド、MAT-303、MT-3724、その他 ・用途別分析2016年-2026年：クリニック、病院、その他 ・B細胞慢性リンパ性白血病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・B細胞慢性リンパ性白血病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・B細胞慢性リンパ性白血病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・B細胞慢性リンパ性白血病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・B細胞慢性リンパ性白血病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The B-Cell Chronic Lymphocytic Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global B-Cell Chronic Lymphocytic Leukemia Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global B-Cell Chronic Lymphocytic Leukemia Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
B-Cell Chronic Lymphocytic Leukemia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
AMG-319
ATTCK-20
IDD-002
JNJ-64052781
Lenalidomide
MAT-303
MT-3724
Others
Market segment by Application, can be divided into
Clinic
Hospital
Others
Market segment by players, this report covers
AB Science SA
Amgen Inc.
Celgene Corporation
Dynavax Technologies Corporation
Eisai
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
iDD biotech SAS
Immunomedics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Molecular Templates Inc.
Noxxon Pharma AG
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe B-Cell Chronic Lymphocytic Leukemia Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of B-Cell Chronic Lymphocytic Leukemia Treatment, with revenue, gross margin and global market share of B-Cell Chronic Lymphocytic Leukemia Treatment from 2019 to 2021.
Chapter 3, the B-Cell Chronic Lymphocytic Leukemia Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and B-Cell Chronic Lymphocytic Leukemia Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe B-Cell Chronic Lymphocytic Leukemia Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of B-Cell Chronic Lymphocytic Leukemia Treatment
1.2 Classification of B-Cell Chronic Lymphocytic Leukemia Treatment by Type
1.2.1 Overview: Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Type in 2020
1.2.3 AMG-319
1.2.4 ATTCK-20
1.2.5 IDD-002
1.2.6 JNJ-64052781
1.2.7 Lenalidomide
1.2.8 MAT-303
1.2.9 MT-3724
1.2.10 Others
1.3 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market by Application
1.3.1 Overview: Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size & Forecast
1.5 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast by Region
1.5.1 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Region, (2016-2021)
1.5.3 North America B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 B-Cell Chronic Lymphocytic Leukemia Treatment Market Drivers
1.6.2 B-Cell Chronic Lymphocytic Leukemia Treatment Market Restraints
1.6.3 B-Cell Chronic Lymphocytic Leukemia Treatment Trends Analysis
2 Company Profiles
2.1 AB Science SA
2.1.1 AB Science SA Details
2.1.2 AB Science SA Major Business
2.1.3 AB Science SA B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.1.4 AB Science SA B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AB Science SA Recent Developments and Future Plans
2.2 Amgen Inc.
2.2.1 Amgen Inc. Details
2.2.2 Amgen Inc. Major Business
2.2.3 Amgen Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.2.4 Amgen Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Amgen Inc. Recent Developments and Future Plans
2.3 Celgene Corporation
2.3.1 Celgene Corporation Details
2.3.2 Celgene Corporation Major Business
2.3.3 Celgene Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.3.4 Celgene Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Celgene Corporation Recent Developments and Future Plans
2.4 Dynavax Technologies Corporation
2.4.1 Dynavax Technologies Corporation Details
2.4.2 Dynavax Technologies Corporation Major Business
2.4.3 Dynavax Technologies Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.4.4 Dynavax Technologies Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Dynavax Technologies Corporation Recent Developments and Future Plans
2.5 Eisai
2.5.1 Eisai Details
2.5.2 Eisai Major Business
2.5.3 Eisai B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.5.4 Eisai B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eisai Recent Developments and Future Plans
2.6 Elsalys Biotech SAS
2.6.1 Elsalys Biotech SAS Details
2.6.2 Elsalys Biotech SAS Major Business
2.6.3 Elsalys Biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.6.4 Elsalys Biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Elsalys Biotech SAS Recent Developments and Future Plans
2.7 F. Hoffmann-La Roche Ltd.
2.7.1 F. Hoffmann-La Roche Ltd. Details
2.7.2 F. Hoffmann-La Roche Ltd. Major Business
2.7.3 F. Hoffmann-La Roche Ltd. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.7.4 F. Hoffmann-La Roche Ltd. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.8 iDD biotech SAS
2.8.1 iDD biotech SAS Details
2.8.2 iDD biotech SAS Major Business
2.8.3 iDD biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.8.4 iDD biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 iDD biotech SAS Recent Developments and Future Plans
2.9 Immunomedics, Inc.
2.9.1 Immunomedics, Inc. Details
2.9.2 Immunomedics, Inc. Major Business
2.9.3 Immunomedics, Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.9.4 Immunomedics, Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Immunomedics, Inc. Recent Developments and Future Plans
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.10.4 Johnson & Johnson B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Johnson & Johnson Recent Developments and Future Plans
2.11 Juno Therapeutics Inc.
2.11.1 Juno Therapeutics Inc. Details
2.11.2 Juno Therapeutics Inc. Major Business
2.11.3 Juno Therapeutics Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.11.4 Juno Therapeutics Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Juno Therapeutics Inc. Recent Developments and Future Plans
2.12 Molecular Templates Inc.
2.12.1 Molecular Templates Inc. Details
2.12.2 Molecular Templates Inc. Major Business
2.12.3 Molecular Templates Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.12.4 Molecular Templates Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Molecular Templates Inc. Recent Developments and Future Plans
2.13 Noxxon Pharma AG
2.13.1 Noxxon Pharma AG Details
2.13.2 Noxxon Pharma AG Major Business
2.13.3 Noxxon Pharma AG B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
2.13.4 Noxxon Pharma AG B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Noxxon Pharma AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 B-Cell Chronic Lymphocytic Leukemia Treatment Players Market Share
3.2.2 Top 10 B-Cell Chronic Lymphocytic Leukemia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 B-Cell Chronic Lymphocytic Leukemia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Application (2016-2021)
5.2 B-Cell Chronic Lymphocytic Leukemia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2026)
6.2 North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2026)
6.3 North America B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Country
6.3.1 North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2026)
6.3.2 United States B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2026)
7.2 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2026)
7.3 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Country
7.3.1 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2026)
7.3.2 Germany B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.3 France B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Region
8.3.1 Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Region (2016-2026)
8.3.2 China B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.5 India B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2026)
9.2 South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2026)
9.3 South America B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Country
9.3.1 South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Market Size by Country
10.3.1 Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE B-Cell Chronic Lymphocytic Leukemia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Region (2021-2026)
Table 6. AB Science SA Corporate Information, Head Office, and Major Competitors
Table 7. AB Science SA Major Business
Table 8. AB Science SA B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 9. AB Science SA B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Amgen Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Amgen Inc. Major Business
Table 12. Amgen Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 13. Amgen Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 15. Celgene Corporation Major Business
Table 16. Celgene Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 17. Celgene Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Dynavax Technologies Corporation Corporate Information, Head Office, and Major Competitors
Table 19. Dynavax Technologies Corporation Major Business
Table 20. Dynavax Technologies Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 21. Dynavax Technologies Corporation B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eisai Corporate Information, Head Office, and Major Competitors
Table 23. Eisai Major Business
Table 24. Eisai B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 25. Eisai B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Elsalys Biotech SAS Corporate Information, Head Office, and Major Competitors
Table 27. Elsalys Biotech SAS Major Business
Table 28. Elsalys Biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 29. Elsalys Biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 31. F. Hoffmann-La Roche Ltd. Major Business
Table 32. F. Hoffmann-La Roche Ltd. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 33. F. Hoffmann-La Roche Ltd. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. iDD biotech SAS Corporate Information, Head Office, and Major Competitors
Table 35. iDD biotech SAS Major Business
Table 36. iDD biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 37. iDD biotech SAS B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Immunomedics, Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Immunomedics, Inc. Major Business
Table 40. Immunomedics, Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 41. Immunomedics, Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 43. Johnson & Johnson Major Business
Table 44. Johnson & Johnson B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 45. Johnson & Johnson B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Juno Therapeutics Inc. Corporate Information, Head Office, and Major Competitors
Table 47. Juno Therapeutics Inc. Major Business
Table 48. Juno Therapeutics Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 49. Juno Therapeutics Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Molecular Templates Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Molecular Templates Inc. Major Business
Table 52. Molecular Templates Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 53. Molecular Templates Inc. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Noxxon Pharma AG Corporate Information, Head Office, and Major Competitors
Table 55. Noxxon Pharma AG Major Business
Table 56. Noxxon Pharma AG B-Cell Chronic Lymphocytic Leukemia Treatment Product and Solutions
Table 57. Noxxon Pharma AG B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) by Players (2019-2021)
Table 59. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Share by Players (2019-2021)
Table 60. Breakdown of B-Cell Chronic Lymphocytic Leukemia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. B-Cell Chronic Lymphocytic Leukemia Treatment Players Head Office, Products and Services Provided
Table 62. B-Cell Chronic Lymphocytic Leukemia Treatment Mergers & Acquisitions in the Past Five Years
Table 63. B-Cell Chronic Lymphocytic Leukemia Treatment New Entrants and Expansion Plans
Table 64. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) by Type (2016-2021)
Table 65. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Share by Type (2016-2021)
Table 66. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Forecast by Type (2021-2026)
Table 67. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021)
Table 68. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Forecast by Application (2021-2026)
Table 69. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 74. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 87. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 88. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 89. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 90. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 91. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 92. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. B-Cell Chronic Lymphocytic Leukemia Treatment Picture
Figure 2. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Type in 2020
Figure 3. AMG-319
Figure 4. ATTCK-20
Figure 5. IDD-002
Figure 6. JNJ-64052781
Figure 7. Lenalidomide
Figure 8. MAT-303
Figure 9. MT-3724
Figure 10. Others
Figure 11. B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Application in 2020
Figure 12. Clinic Picture
Figure 13. Hospital Picture
Figure 14. Others Picture
Figure 15. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Region (2016-2026)
Figure 18. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Region in 2020
Figure 19. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. B-Cell Chronic Lymphocytic Leukemia Treatment Market Drivers
Figure 25. B-Cell Chronic Lymphocytic Leukemia Treatment Market Restraints
Figure 26. B-Cell Chronic Lymphocytic Leukemia Treatment Market Trends
Figure 27. AB Science SA Recent Developments and Future Plans
Figure 28. Amgen Inc. Recent Developments and Future Plans
Figure 29. Celgene Corporation Recent Developments and Future Plans
Figure 30. Dynavax Technologies Corporation Recent Developments and Future Plans
Figure 31. Eisai Recent Developments and Future Plans
Figure 32. Elsalys Biotech SAS Recent Developments and Future Plans
Figure 33. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 34. iDD biotech SAS Recent Developments and Future Plans
Figure 35. Immunomedics, Inc. Recent Developments and Future Plans
Figure 36. Johnson & Johnson Recent Developments and Future Plans
Figure 37. Juno Therapeutics Inc. Recent Developments and Future Plans
Figure 38. Molecular Templates Inc. Recent Developments and Future Plans
Figure 39. Noxxon Pharma AG Recent Developments and Future Plans
Figure 40. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Share by Players in 2020
Figure 41. B-Cell Chronic Lymphocytic Leukemia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share in 2020
Figure 43. Global Top 10 Players B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Share by Type in 2020
Figure 46. Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Share Forecast by Type (2021-2026)
Figure 47. Global B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Share by Application in 2020
Figure 48. Global B-Cell Chronic Lymphocytic Leukemia Treatment Market Share Forecast by Application (2021-2026)
Figure 49. North America B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 50. North America B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 51. North America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 52. United States B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 56. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 57. Europe B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 58. Germany B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Region (2016-2026)
Figure 66. China B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 73. South America B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 74. South America B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 75. Brazil B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa B-Cell Chronic Lymphocytic Leukemia Treatment Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa B-Cell Chronic Lymphocytic Leukemia Treatment Revenue Market Share by Country (2016-2026)
Figure 80. Turkey B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE B-Cell Chronic Lymphocytic Leukemia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
世界の慢性リンパ性白血病（CLL）治療市場予測（～2024年） Treatment options for chronic lymphocytic leukemia (CLL) vary greatly, depending on the person’s age, the disease risk group, and the reason for treating (for example, which symptoms it is causing). Scope of the Report: The global Chronic Lymphocytic Leukemia (CLL) Treatment market is valued at xx m…- 急性リンパ性/リンパ芽球性白血病（ALL）治療薬の世界市場… Scope of the Report: The global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in fol…
- B細胞リンパ腫2阻害剤の世界市場 2019年版：種類別（併用療法、単剤療法）、用途別（慢性リンパ性白血病、小リンパ球性リンパ腫、急性骨髄性白血病 ） Scope of the Report: The global B-cell lymphoma 2 Inhibitors market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in Chi…
- 世界の小児慢性副鼻腔炎治療市場予測（～2024年） Pediatric chronic Rhinosinusitis is one of the major and common disorder among infants with significant morbidity. Its diagnosis involves sinus symptoms, with prolonged duration requiring standard medical therapy for more than 90 days. The main causative factors for pediatric chronic rhinosinusitis …
- 世界の線維形成性小円形細胞腫瘍治療市場 2021：企業別、地域別、種類・用途別 The Desmoplastic Small Round Cell Tumor Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optim…